Structure Encountered

Galux

AI-driven protein therapeutics design platform for de novo antibody generation.

Galux benchmarked GaluxDesign vs JAM-2 and Chai-2: 8/9 targets validated as full IgGs, nanomolar BLI affinities for 7/8.

SIGNAL·Comparative benchmarking, internal study·8/9 targets vs JAM-2 5/9 and Chai-2 4/9·SCORE 76·19 MAY 2026 · 12:47 UTC

● CAPTURE — IMAGE INCOMINGFRAME 01 / 01

STRUCT. / GALUX

/ Seoul, South Korea

CAPT. / 19.05.26 12:47:05Z

SIGNAL / 76 / 100

Image relayed by The Biotech Voyager during pass over structure Galux. Resolution as transmitted.

001Vital Statistics

DATA LOCKED

Designation

Galux

Coordinates

Seoul, South Korea

Stage

Preclinical

Type

Tools Services

Modalities

AI/ML · antibody · protein therapeutic

Therapeutic area

Oncology · Fibrosis · Metabolic · Immunology

002Signature Detected

EVENT DETECTED

Event type

Comparative benchmarking, internal study

Magnitude

8/9 targets vs JAM-2 5/9 and Chai-2 4/9

Lead

Galux

Participating

Internal study, 9 targets from public de novo antibody design preprints

003Architecture

PLATFORM PROFILE

Target class

De novo antibody design across diverse antigen classes including soluble proteins, GPCRs, and ion channels. GaluxDesign generates antibody sequences from scratch and outputs full-length IgG-format candidates.

Differentiator

Generate's JAM-2 and Chai Discovery's Chai-2 are the western reference AI antibody design platforms. In a head-to-head across nine shared targets, GaluxDesign hit 8 of 9 with experimentally validated binders, JAM-2 hit 5 of 9, and Chai-2 hit 4 of 9. Galux also went one step further and tested in full-length IgG format with BLI-confirmed nanomolar affinities for 7 of 8.

Lead asset

GaluxDesign platform, de novo antibody design

Pipeline depth

Platform company. Co-development agreements with Celltrion and LG Chem. No clinical-stage assets disclosed.

004Voyager Assessment

MACHINE-GENERATED

Internal head-to-head studies have a known bias toward the host. That said, Galux ran 50 designs per target in IgG format with BLI confirmation, which is a higher bar than design success alone. 8 of 9 targets producing binders, and 7 of 8 with low-to-mid nanomolar affinities, would be a strong result if it holds up under external scrutiny. Galux is preclinical, $47M total raised, and partnered with Celltrion and LG Chem. The benchmark publication is a BD play. Watch whether Galux discloses internal pipeline programs or signs a western pharma deal next.

005Adjacent Structures

FRONTIER MAP

Generate Biomedicines· JAM-2 antibody design platformChai Discovery· Chai-2 antibody design platformAbCellera Biologics Inc.· AI antibody discovery, Lilly partnerEarendil Labs· $787M AI bispecific platformHarbour BioMed· AI bispecific, Sanofi partnerCelltrion· Korean biosimilars co-development partnerLG Chem· Korean co-development partner

— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.